Beisheng Pharmaceutical and the Changsan Hospital Hangzhou Branch established a cooperative relationship

On May 10, Rebiosun (Zhejiang) Pharmaceutical Co., Ltd. signed an equity investment agreement with Hangzhou Shuimu Fenghua Venture Capital Partnership, a subsidiary of Zhejiang Tsinghua Yangtze River Delta Research Institute Hangzhou Branch. Hangzhou Shuimu Fenghua invested in Rebiosun (Zhejiang) Pharmaceutical Co., Ltd. , become a shareholder of the company.

Zhejiang Tsinghua Yangtze River Delta Research Institute is the forerunner of Zhejiang's strategy of "introducing famous universities and colleges and building innovative carriers", and it is the first provincial school to build a new innovation carrier in Zhejiang. Relying on the science and technology and talents of Tsinghua University, it is based in Zhejiang, facing the needs of economic and social development in the Yangtze River Delta region, and vigorously carries out scientific and technological innovation, technical services, personnel training and high-tech industrialization. The seven-in-one collaborative innovation concept of "government-industry-university-research-funding application" pioneered by the institute has great practical significance and exemplary role in deepening system reform, promoting regional collaborative innovation and industrialization of high-tech achievements. At present, more than 50 innovative R&D platforms have been established in key fields such as life and health, digital creativity, information technology, and ecological environment, 12 national and provincial key R&D platforms, and 27 national and provincial innovation and entrepreneurship incubation platforms have been established. , as well as a series of comprehensive innovation service platforms such as Scientist Online, Science and Technology Fund of Funds, Science and Technology Insurance, and Haina Talent Support Program, and has also established 11 offshore incubators in the United States, Britain, Germany, Australia and other countries.

Rebiosun (Zhejiang) Pharmaceutical Co., Ltd. is an innovative pharmaceutical and pharmaceutical enterprise dedicated to solving major diseases that are currently difficult to treat such as cardiovascular and cerebrovascular, cerebral apoplexy and other diseases through regenerative medicine methods. The efficiency of differentiation into target cells can induce the regeneration of new blood vessels in the ischemic site, so as to provide curative treatment for coronary heart disease, ischemic stroke and other diseases. At this stage, the company aims to develop a class of innovations that promote the treatment of ischemic stroke Drug application and listing.

Zhejiang Tsinghua Yangtze River Delta Research Institute Hangzhou Branch fully affirms the innovation ability of the scientific research team of Besun, supports and encourages Besun's efforts in solving major and difficult diseases of human beings, and is willing to empower Besun to make use of the abundant resources of Tsinghua University for Besun. Biopharma provides strong support in scientific research, funding and application.

Shao Xiangrong, Vice President of Zhejiang Tsinghua Yangtze River Delta Research Institute and President of Hangzhou Branch, Wu Qian, Director of Cooperation Department of Hangzhou Branch, Head of Hangzhou Shuimu Fenghua Venture Capital Partnership and Head of Beisheng (Zhejiang) Pharmaceutical Co., Ltd. Dr. Li Ming and Huang Haoming and others attended the signing ceremony.